Effective but cost-prohibitive drugs in breast cancer treatment

A clinician's perspective

Authors

  • Jose Bines MD,

    Corresponding author
    1. Instituto Nacional de Cancer, Rio de Janeiro, Brazil
    • Instituto Nacional de Cancer-Brasil, Rua Visconde de Santa Isabel 274, Rio de Janeiro, Brasil
    Search for more papers by this author
    • Dr. Bines has received honoraria from Astra-Zeneca and has acted as either a consultant or in an advisory role for Bristol Myers-Squibb and Astra-Zeneca.

    • Fax: (011) 55-21-2577-6941

  • Alexandru Eniu MD

    1. Department of Breast Tumors, Cancer Institute “Ion Chiricuta,” Cluj-Napoca, Romania
    Search for more papers by this author

  • The views expressed in this article are the results of independent work and do not represent the views of the authors' institutions.

  • Complete financial disclosures are presented at the end of this article.

Abstract

New pharmacologic treatments for early-stage breast cancer have been proven effective, but many of them are cost prohibitive in low economic settings. Differences in breast cancer mortality rates between developed and developing countries may be because of differences in screening and treatment options, some of which may be unavailable or limited by cost constraints in countries with limited resources. It is well recognized that treatment choices have to be made within budgetary constraints, and treatment guidelines that address the need to stratify treatment options by available resources have been published by the Breast Health Global Initiative. Practical treatment choices need to be made based on the best available cost–effective information. This article reviews new and emerging medical strategies that may improve the cost-effectiveness equation. Cancer 2008;113(8 suppl):2353–8. © 2008 American Cancer Society.

Ancillary